Asana BioSciences, LLC Information

Asana BioSciences, a clinical-stage biopharmaceutical company, was founded in 2014 with the mission to develop novel, clinically differentiated, best-in-class products that address unmet medical needs and provide new treatment options for cancer patients and those suffering from inflammatory conditions. Seven successful INDs were filed in a short span after founding of Asana and multiple clinical proof of concepts studies have been completed in oncology and immunology/inflammation therapeutic categories. Gusacitinib (ASN002), Asana’s lead immunology asset, is entering phase 3 development. Asana’s lead oncology asset (ASN007 or ERAS-007) has completed phase 1 trials in cancer patients. Multiple drugs from Asana’s portfolio have already been out-licensed/partnered with other biotech companies for further development and commercialization.